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Background: Ban-Lan-Gen (BLG) is a traditional Chinese herbal medicine. It has been used for the prevention and
treatment of virus-related respiratory diseases such as influenza virus infection. BLG contains some antiviral
compounds, but few evidence-based clinical studies have been conducted to assess its efficacy against influenza.
We assessed the effects of BLG (including efficacy and safety) on the treatment of seasonal influenza in an
evidence-based clinical trial.
Methods/Design: We conducted a randomized, double-blinded, oseltamivir- and placebo-controlled, parallel-design
clinical trial. A total of 177 subjects are going to be recruited after satisfying the criteria: (i) 18 to 65 years of age;
(ii) illness onset within 36 h; (3) axillary temperature ≥38.0°C; and (iv) positive influenza (type A/B) virus test. Subjects will
be assigned randomly into three groups in equal proportions: oseltamivir treatment, BLG granule treatment, and placebo
treatment. Each group receives 5-day treatment and is followed up 1, 3, 5, 7 and 21 days later. Symptoms and patient
compliance are recorded, and virus/serum viral antibodies tested. We will use the primary outcome, secondary outcome,
and safety indicators to evaluate the efficacy and safety of BLG granules in the treatment of seasonal influenza.
Discussion: We have described the first clinical trial for treatment using a single herb against influenza A and B viruses
in China. We will hold a large-scale clinical trial to comprehensively evaluate the effectiveness and safety of BLG against
influenza infection based on the results of this pilot study. And this clinical trial will serve as an example for the study of
other traditional herbal medicines in evidence-based clinical trials.
Trial registration: This study has been registered at ClinicalTrials.gov: NCT02232945 (3 September 2014).
Keywords: Ban-Lan-Gen granule, Seasonal influenza, Oseltamivir, Evidence-based clinical trialBackground
The influenza epidemic
Influenza is an acute respiratory disease caused by highly in-
fectious influenza viruses such as H1N1, H3N2, H5N1,
H7N9, and influenza B. It has a strong capability of spreading
globally, leading to adverse health effects [1]. Such respiratory
diseases are usually caused by type A or type B influenza, and* Correspondence: jeffyah@163.com; nanshan@vip.163.com
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unless otherwise stated.the symptoms include headache, muscle aches, cough, and
sudden fever [2]. Infection by the pandemic (H1N1) 2009
virus emerged initially in Mexico in early 2009 and has be-
come a global pandemic [3-5]. Now, influenza A (H1N1,
H3N2 and pandemic (H1N1) 2009) and influenza B have in-
duced co-infection worldwide, thereby causing considerable
panic among general populations.Drug resistance in Western medicine
M2 ion channel blockers (for example, amantadine and
rimantadine) and neuraminidase (NA) inhibitors (for ex-
ample, oseltamivir, zanamivir, and peramivir) are com-
monly used for the prevention and treatment of influenza
[6]. Amantadine and rimantadine, however, have been
associated with neurologic toxicities and gastrointestinalis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been found to result in drug-resistant strains [8]. Up to
2003, M2-resistant variants had even spread to countries
where these drugs are used infrequently [9]. Pandemic
(H1N1) 2009 has demonstrated resistance to amantadine
and rimantadine [10,11]. Our previous study suggested
that clinical isolates of H1N1 and H3N2 developed aman-
tadine resistance at 93.1% and 100%, respectively, in
Guangzhou, China [12]. NA inhibitors, in comparison
with M2 ion channel blockers, are more commonly used
but they (i) can also cause respiratory side effects and even
death (for example, oseltamivir [13]) owing to intensive
use and (ii) have a higher barrier for resistance if overused.
A survey from 1999 and 2007 showed a very low level
(<1%) of resistance to oseltamivir [10,14], but a survey be-
tween 2008 and 2009 reported the resistance to be ≥90%
[15-18]. Resistance to zanamivir has been (albeit rarely)
reported among immunodeficient patients [19,20]. Whether
such antiviral agents can be used to address influenza epi-
demics is not clear. Furthermore, the true effectiveness of
oseltamivir treatment against influenza is controversial [21].
Traditional Chinese herbal medicine and basic research
Traditional Chinese herbal medicine (TCHM) is richly
used in Chinese clinics and widely used to treat and pre-
vent respiratory infection disease. Unlike Western medi-
cine, TCHM has different mechanisms and targets of
action and, potentially, could be used to overcome drug
resistance and side effects. Therefore, exporting the new
antiviral medicine from TCHM will be a new choice. For
example, the starting material (shikimic acid) for the
synthesis of the oseltamivir can be obtained from Illi-
cium verum, which is a type of TCHM (Tamiflu™, Roche,
Basel, Switzerland).
Among the many types of TCHMs, Ban-Lan-Gen
(BLG) has a thousand-year history of use for the preven-
tion and treatment of respiratory tract infections (par-
ticularly respiratory viral diseases). BLG was highlighted
as a classic antiviral and anti-influenza agent in the
People’s Republic of China Pharmacopoeia in 1979 and
2010, respectively. Additionally, BLG was one of the
eight major medicines recommended by the Chinese
government for the prevention and control of severe
acute respiratory syndrome (SARS).
Several clinical studies have evaluated the efficacy of
BLG granules on treatment of acute pharyngitis (among
which, 50% are caused by viruses), infection of the upper
respiratory tract, and influenza H1N1 [22,23]. However,
none of those studies were evidence-based clinical trials.
The Isatis indigotica root (IIR) is the single largest
component of BLG granules. Our previous studies sug-
gested that the Isatis indigotica root polysaccharide
(IRPS) and clemastanin B derived from IIR can inhibit
various subtypes of the influenza virus in vitro. Inhibitingthe hemagglutinin (HA) of the virus at its early stage of in-
fection is an important antiviral mechanism of IIR [24-26].
In vivo experiments revealed clemastanin B to significantly
inhibit pneumonia and virus proliferation in lung tissue
(Zifeng Yang and Zhengtu Li, unpublished work). We also
found that the lignin group (IIR isolated) inhibits the nu-
clear factor-kappa B signaling activated by the influenza
virus and blocks exportation of the NP protein of the
influenza virus (article in press). Other studies have also
shown that indirubin (also contains IIR) and its derivatives
have antiviral and anti-inflammatory effects in infection
due to the influenza A (H5N1) virus [27].
Study aims
Studies have suggested that BLG and its active ingredients
may inhibit the influenza virus. Little concrete clinical
evidence has been provided, however, for the efficacy of
BLG in the treatment of seasonal influenza. We wished to
evaluate the efficacy and safety of BLG granules for the
treatment of seasonal influenza in an evidence-based
clinical trial.
Methods/Design
Ethical approval of the study protocol was granted
from the Ethics Committee of the First Affiliated Hos-
pital of Guangzhou Medical University (number, 2011014;
Guangzhou, China), and informed consent was obtained
from each participant.
Design
This clinical study was a randomized, double-blind, double
control trial that tested drugs and placebo. Noninferiority
(versus positive control) and superiority (versus placebo
control) trials were conducted. Patients with positive tests
for the influenza virus (rapid detection of antigens to the
influenza virus before enrollment, but if detection of nu-
cleic acid of the influenza virus or cultivation of the influ-
enza virus was inconsistent, the patient was excluded)
were assigned randomly into three groups of equal pro-
portions (1:1:1). Groups were: oseltamivir treatment (posi-
tive control), BLG granule treatment (test group) and
placebo group. Patients will accept 5-day treatment and
21-day observation. Patient follow-up was undertaken on
days 1, 3, 5, 7, 21 (Table 1 and Figure 1). Specific items
that were collected for each follow-up period are outlined
in Table 1.
Setting
Different aspects of the study activities will be conducted
at different sites. For instance, patient enrollment, as well
as collection of specimens and data, will be conducted in
the Outpatient Department of the First Affiliated Hospital
of Guangzhou Medical University. Biochemical examina-
tions will be undertaken in the laboratories of the First
Table 1 Follow-up chart of treatment using ban-lan-gen granules against seasonal influenza





Visit 1 Day 3 + 1
after administration
Visit 2 Day 5 + 1
after administration
Visit 3 Day 7 + 1
after administration
Visit 4 Day 21 + 7
after administration
Acquisition of basic medical history
Informed consent X
Basic conditions X
Symptoms X X X X
Inclusion and exclusion criteria X
Safety observations
Vital signs X X
Electrocardiography X a a X
Chest radiograph X a a a
Laboratory inspection X a a X
Record adverse events X X X X X
Efficacy
Record influenza symptoms X X X X
Virology
Rapid diagnostic tests X
Real-time PCR analyses X X X X
Viral isolation culture X X X X
Viral antibody titer X X
Other
Grouping and giving drugs X
Administer drugs X X X
Distribute patient diary card X
Accompanying treatment A A a a
Compliance X X X X
Inspection results X X
Original record completion X X X X X
Recover study drug X
Recover patient diaries X
CRF review, recovering and test summary X
X, must implement; a, necessary to implement.
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Virus testing will be carried out in the Clinical Virology
Division of the State Key Laboratory of Respiratory
Disease, Guangzhou, China. Data analyses will be done at
Southern Medical University, Guangzhou, China.
Number of participants and specimen collection
Recommendations from the World Health Organization
for influenza-like illnesses (ILIs) were used as the basis
for influenza surveillance. If a patient presents with an
acute cough and fever, clinicians must be highly vigilant
to test for infections caused by the influenza virus. Ingeneral, the rate of ILI cases that lead to a clinical diag-
nosis of influenza infection is approximately 18 to 80%,
which is higher than other clinical diagnoses, for ex-
ample, acute infections of the upper respiratory tract
[28]. We selected adult ILI patients for inclusion into
the study. The study was designed to enroll 177 cases.
Specimen collection included pharyngeal/throat swabs
and blood samples. Pharyngeal/throat secretions were
obtained from the upper respiratory tract of each patient
[29]. Pharyngeal/throat swabs will be used to test the
mRNA of the influenza virus; the virus will be cultured.
Blood samples will be used to test viral antibodies.
Figure 1 Study flowchart. Participants with a rapid diagnosis of influenza will be recruited, and they will be assigned randomly into three
different groups. All participants will accept the 5-day treatment and 21-day follow-up period observation. The data were collected to determine
the treatment efficacy and safety of Ban-Lan-Gen (BLG).
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Staff training
Personnel who participate directly in this study will be
adequately trained to ensure the safety of the patients,
blinding of the study design, data quality, and adherence
to the study protocol. Personnel follow guidelines for
good clinical practice (GCP).
Recruitment, screening, and enrollment
We will follow criteria to recruit, screen, enroll and re-
ject patients. Patients will be enrolled if they conform to
all inclusion criteria. However, they will not be enrolled
if they have one of the exclusion criteria, rejection cri-
teria, or termination standards. Furthermore, it is the re-
sponsibility of participant to cooperate with the doctor’s
treatment. Additionally, they should cooperate with our
follow-up and provide us with information that is not
beyond the ethical approval.
Inclusion and exclusion criteria
Inclusion criteria are patients (i) with confirmed infec-
tion by the influenza A (H1N1, H3N2) or influenza B
virus according to real-time polymerase chain reaction(PCR) or viral culture; (ii) aged 18 to 65 years; axillary
temperature ≥38°C; at least two constitutional symptoms
(headache, chill, myalgia or fatigue) and one respiratory
symptom (cough, sore throat, or rhinitis) [30,31]; (iii)
illness onset within 36 h; and (iv) granting of written in-
formed consent. Exclusion criteria are detailed in Table 2.Rejection criteria and termination standards
Rejection criteria were (i) not meeting inclusion or exclu-
sion criteria; (ii) withdrawal of informed consent; (iii) not
receiving follow-up care after selection; or (iv) serious vio-
lation of the program (that is, incorrect administration
leading to effects that cannot be judged).
Termination standards refer to patients who meet the
inclusion criteria, but must be terminated during the
trail and who are included in the final statistical analyses.
Termination standards are detailed in Table 3.Drugs and usage
Oseltamivir treatment group
The oseltamivir treatment group will receive one oselta-
mivir capsule, (75 mg/per capsule), twice a day [29], 30
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
(1) With confirmed infection by the influenza A (H1N1, H3N2) or influenza
B virus according to real-time polymerase chain reaction (PCR) or viral
culture
(1) Age <18 years or >65 years
(2) Confirmed bronchitis, pneumonia, pleural effusion and interstitial lung
disease via chest imaging (radiograph or CT)
(2) Aged 18 to 65 years; axillary temperature ≥38°C and at least two
constitutional symptoms (headache, chill, myalgia or fatigue) and one
respiratory symptom (cough, sore throat, or rhinitis)
(3) Routine screening tests of blood with leukocyte readings >10.0 × 109/L
or neutrophil count ≥80%
(4) Suppurative tonsillitis or purulent sputum
(3) Illness onset within 36 h (5) Underling primary disorders such as hematological disease, chronic
obstructive pulmonary disease (FEV1/FVC <70%, FEV1/predicated value
<50%; or respiratory failure or right-heart failure), hepatic disease
(ALT or AST ≥ triple ULN), renal disease (serum creatinine > 2 mg/dL)
or chronic congestive heart failure (NYHA III to IV)
(4) Granting of written informed consent
(6) Previous administration of antiviral drugs (amantadine, rimantadine,
zanamivir, or oseltamivir phosphate) before disease onset and study
enrollment, or administration of traditional Chinese herbal medicine
or proprietary Chinese medicine. Administration of BLG granules
within 1 week before disease onset
(7) Allergy to study medication(s)
(8) Women who are pregnant, or may possibly become pregnant, or who
are lactating with a positive urine pregnant test, or with a body mass
index (BMI) ≥25 kg/m2
(9) The immunodeficient: malignant tumor; organ or bone-marrow
transplantation; AIDS; or taken immune inhibitors during the
last 3 months
(10) Suspicion or history of alcohol/drug abuse
(11) Participation in another clinical trial <3 months before study
randomization
(12) Acute respiratory infection, otitis, or nasosinusitis 2 weeks before
study enrollment
(13) Vaccination with the influenza vaccine within 6 months
(14) Other reasons at the investigator’s discretion
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BLG granules.
Ban-Lan-Gen treatment group
The BLG group will receive two bags of BLG granules
(10 g/per bag), twice a day (the dosage is set accordingTable 3 Termination standards
Criteria
1 The patient’s illness becomes severe, and the severity meets one of
the following criteria: (i) persistent high fever for >3 days (≥39°C);
(ii) Severe cough, purulent sputum, bloody sputum, or pectoralgia;
(iii) rapid breathing, trouble in breathing, lip cyanosis; (iv) alternation
of consciousness (that is, drowsiness, restlessness, convulsions);
(v) severe vomiting, diarrhea, dehydration; (vi) imaging confirms
signs of pneumonia; (vii) levels of myocardial enzymes, such as
creatine kinase (CK), creatine kinase isoenzyme (CK-MB) elevate
rapidly; (viii) underlying diseases are exacerbated significantly.
2 Death (including deaths due to influenza and other causes of death)
3 Antibiotic treatment is required (bacterial pneumonia, tympanitis,
nasosinusitis secondary to influenza)
4 Serious events occur
5 Other health reasonsto the regulations of the China Food and Drug adminis-
tration.), 30 minutes after eating, taken with an analo-
gous oseltamivir capsule.
Placebo group
The placebo group will receive BLG analogous granules,
twice a day, 30 min after eating, taken with an analogous
oseltamivir phosphate capsule.
The BLG granules and the BLG analogous granules
were produced according to the quality requirements of
the People’s Republic of China Pharmacopoeia (Additional
files 1 and 2). Furthermore, the placebo includes white
powdered sugar (41.1%), brown powdered sugar (22.6%),
amylum (16.43%), dextrin (10.27%), caramel syrup (1.4%),
and lemon yellow (8.2%).
All drugs were packaged by Hutchisom Whampoa
Guangzhou Baiyunshan Chinese Medicine Company
Limited (Guangzhou, China) according to the require-
ments of a double-blind, double-simulation test. The
drugs used in this double-blinded trial were counted and
sorted by a third party (Southern Medical University,
China). All drugs were in the period of validity.
Table 4 Classification of disease severity
Classification Features
1. Mild Can continue to participate in the clinical trial, without
obstacles in the activities of daily living
2. Moderate Has certain obstacles to daily life, but not to the point of
completely diminished function
3. Severe The extent of obstacles in the activities of daily living
has led to the risk of permanent disability, and
appropriate measures are needed to mitigate medical
issues
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standards for using other drugs, which are axillary
temperature ≥38.5°C that continues more than 4 hours
and does not degrade with physical cooling or body
temperature is gradually raised ≥ 39°C. When these stan-
dards are met, the symptoms are treated as indicated:
fever: paracetamol; white sputum, bromhexine; and mild
asthmatic symptoms, long-term theophylline. With these
exceptions, no other drugs can be used. Furthermore,
detailed information on the drug use will be registered
in the case report form (CRF).
Outcome measurements
Drug efficacy was determined using patient symptoms,
body temperature, and virus detection.
Primary outcome
The first primary outcome is the duration of the illness
and will be measured in hours. Duration of illness is
defined as the time from symptom onset to alleviation of
the influenza-like symptoms: nasal obstruction, running
nose, cough, sore throat, headache, fatigue, myalgia, chills
and sweating. The definition of symptom alleviation is
influenza-like symptoms score ≤1 (mild) and maintenance
of stable symptoms for more than 24 h [30,32].
Another primary outcome is the time to deferves-
cence, which is measured in hours. The time from the
first dose of the study medication to the time when the
body temperature decreases to <37.4°C is defined as
‘defervescence,’ and when it is sustained for ≥24 h, it is
defined as ‘complete defervescence’ [30,32].
Secondary outcome
Five secondary endpoints are being considered. The first
is the duration of viral shedding. This endpoint is de-
fined as the time from illness onset to the first time the
viral nucleic acid test is negative. The second endpoint is
disease severity. It is assessed by an area under the curve
(AUC) analysis of nine influenza-like symptom scores
[29]. The AUC is calculated as the product of the daily
symptom scores multiplied by the duration of illness.
The third endpoint is the frequency of acetaminophen
usage. The fourth endpoint is the prevalence of second-
ary influenza complications. These are otitis, bronchitis,
pneumonia, nasosinusitis, suppurative tonsillitis, acute
parotitis, Reye’s syndrome, central nervous system dis-
ease, myocarditis, pericarditis, acute myositis, and toxic
shock syndrome. The final endpoint was an economic
evaluation.
Safety evaluation
Safety is evaluated using vital signs, cardiopulmonary
signs, adverse reactions, electrocardiography, and clinical
laboratory tests (including liver and kidney functionsand myocardium enzyme). These indices are compared
before and after the drugs were taken.
Evaluation of adverse events
An adverse event refers to any adverse, unintended or
unplanned effects on vital signs, symptoms, diseases, or
laboratory indices that change after participants have en-
rolled in the clinical trial. An adverse event is not neces-
sarily related to the drugs. Adverse events are divided
into three levels: mild, moderate and severe (Table 4).
The cause-and-effect relationship between an adverse
event and study drugs is evaluated according to whether
the agent (i) causes death; (ii) imperils life; (iii) leads to
hospitalization or extends the duration of the hospital
stay; (iv) is teratogenic or causes birth defects; (v) causes
a permanent handicap; or (vi) is carcinogenic (Table 5).
All serious adverse events must be reported within 24 h
to the State Food and Drug Administration as well as
the ethics committee.
Data management
Management of the analyses of data entry by a third party
(Southern Medical University, China)
Management of the data entry and analyses will be
undertaken by a specific data manager responsible for
building the study database and program settings. Data
will be inputted twice and confirmed by two keyboard
operators who have received special training. After veri-
fication of the case report forms (CRFs), identified input
errors will be corrected until there are no differences in
the database. Uncertainties can be discussed with the
researcher using CRF question forms. These question
forms shall be completed by the researcher within a spe-
cified time limit as well as being signed and dated. Com-
pleted question forms will be sent to the Department Of
Database Management. The data manager will revise
and verify the feedback from the researcher, update the
database, and resend the form (if necessary). After con-
firming the veracity of the database via blind review,
locked data will not be corrected. Data revision after
locking will be confirmed by the study promoters, re-
searchers, program manager, statistician, and the data
manager with a written declaration and will be corrected
Table 5 Classification of adverse events
Classification Feature
1. Definite Use of the experimental drug has a definite relationship
with time.
Similar pharmacologic effects of the drug or
experimental drug are well known.
There is no other plausible cause owing to disease or
other explanations.
2. Probable Use of the experimental drug has a reasonable
relationship with time.
Similar pharmacologic effects of the drug or
experimental drug are well known.
It is difficult to identify a cause owing to disease or
other explanations.
3. Possible Use of the experimental drug has a reasonable
relationship with time.
The adverse event may be caused by disease or other
explanations.
4. Remote There is a connection between time and test drug.
It is easy to explain through disease or the main causes
of a disease.
5. Unrelated There is no connection between time and the test drug.
The adverse event is definitely caused by other reasons,
and not the test drug.
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be evaluated by confirming the intent-to-treat population
(ITTP), modified intent-to-treat population (MITTP), per-
protocol population (PPP) and safety analysis population
(SAP). The decision will be approved by the data manager,
study promoter, and researchers, and will end with
unblinding after locking the database.Patient groups for data analyses
Intent-to-treat population The intent-to treat popula-
tion will include those patients who agree to enroll in
the study and sign an informed consent form.Modified intent-to-treat population The modified
intent-to-treat population includes those patients who
used the test drug at least once during randomization,
and data will be used to indicate efficacy after
intervention.Per protocol population The per protocol population
includes those cases that meet the inclusion criteria, are
in full accordance with the test program (or violate the
protocol only slightly), complete the trial and complete
the CRF. The PP is used to analyze the main indicators
for evaluating efficacy and to examine the consistency of
the results from the MITT.Safety analysis population For the safety analysis popu-
lation, data will demonstrate efficacy after intervention
for those patients who use the test drug at least once
during randomization. In this study, the baseline data,
MITT analyses and main indicators for treatment are
employed in PP analyses, but the conclusion from MITT
analyses is also evaluated. When undertaking PP ana-
lyses, if there are missing data, the last observation
carried forward (LOCF) approach will be adopted to
complete the dataset. For laboratory data, adverse events
and side effects, we will use SA analyses, and the SAP
will be the denominator for the prevalence of adverse
reactions.
Statistical analyses
The software used for statistical analyses will be SPSS
v17.0 (IBM, Armonk, NY, USA) or SAS v9.2 (SAS Insti-
tute, Cary, NC, USA).
All statistical inferences will be determined using two-
sided tests. P <0.05 will be considered significant, and
95% confidence intervals will be used.
Efficacy analyses will use LOCF to compensate for
cases not fully covered during treatment. The LOCF ap-
proach uses the last data observed, which is transferred
to the database to obtain a complete dataset. The safety
assessment will not evaluate missing data.
A comparison between the dropout rate and dropout
rate caused by adverse events will be undertaken using
the Pearson’s χ2test.
Data will be described as the mean, standard deviation,
and confidence intervals. If necessary, minimum, max-
imum, P25, P75, and median values will be provided.
Paired measurement data will also show the differences
between the mean and standard deviation. When using
nonparametric methods, median and mean values will
be provided. Count data will be described using the fre-
quency distribution and corresponding percentage. Data
of concentrations will be described using the frequency
distribution and the corresponding percentage, as well
as median and average values. Qualitative information
will be described using the positive rate, the number of
positive cases, and the denominator.
Baseline data analyses (two sets) will include demo-
graphic indicators, as well as general, primary and sec-
ondary indicators before intervention. Measurement
data will be described using a t-test or t’ test (if the vari-
ance is absent). Count data will be described using the
Pearson’s χ2test. Rating data will be described using the
two-sample Wilcoxon rank sum test.
With respect to analyses of effectiveness, for quantita-
tive variables, comparisons between groups will be under-
taken using repeated measures analysis of variance and
covariance analysis. For qualitative variables, comparisons
between groups will be tested using the Pearson’s χ2test,
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variables, comparisons between groups will be tested
using the Kruskal-Wallis test, regression analysis center
effect via the CMH test, or grade logistics.
In terms of center effect analyses, the GLM method
will be used for quantitative indicators and CMH
methods for qualitative indicators. Rating variables will
be evaluated and corrected using a logistic regression
model.
With regard to subgroup analyses, depending on the
circumstances, factors that cannot be excluded may have
an effect on the prognosis.
For safety analyses, the prevalence of adverse events in
the two groups will be compared using the Pearson’s
χ2test, as well as listing and describing the events that
occur during the trial. A description of laboratory test
results before and after the test will be described as
normal/abnormal changes, as well as the relationship
between the abnormal changes and the test drug; these
changes will be stated.
Safety and ethics
The drugs used in this clinical trial (BLG granules and
oseltamivir) have been approved for clinical use, so there
is no potential safety hazard. To ensure that study pa-
tients receive effective treatment during rehabilitation,
the placebo control group will be provided basic drugs.
Before study commencement, we will explain in detail
the research purpose, methods and processes. Satisfac-
tory answers to any questions from the subjects, after
obtaining written informed consent, will be included.
Also, the center will focus on the purpose, application
and execution of the study. Researchers will accept the
research plan, treatment procedure, patients, research
schedule, CRF and written informed consent. During the
trial, the clinical unit must comply with GCP and the
scheme of the clinical trial. Pharmaceutical supervisory
and administrative departments will occasionally con-
duct audits and inspections and will cooperate with the
sponsor to send medical examiners. Any moderate or
serious adverse events will be reported to the Ethics
Committee.
Discussion
Treatment effectiveness, safety assurance and patient
affordability are the key factors for any drugs, including
Western medicines and TCHMs. This projected clinical
trial will provide evidence as to whether BLG granules
are suitable and safe for treating and preventing seasonal
influenza.
BLG seems to display a clinical effect during the early
onset of illness. Our previous study showed that IPRS,
clemastanin B and lignin, which are separated from IIR,
have antiviral roles in the early infection stage of theinfluenza virus [24-26]. Accordingly, we defined the time
of illness onset to be <36 hours. Unfortunately, this cri-
terion made patient recruitment quite difficult. However,
this design, which is based on a combination of trad-
itional medical experience and modern pharmacological
study, should allow us to discover the objective treat-
ment effectiveness of BLG.
The safety of TCHM is attracting major attention.
First, in our study, BLG granules are used only for 5 days
in the acute phase, so that it may be safe for humans.
Second, we evaluate the safety of BLG based on changes
in liver and kidney function after treatment. In addition,
western medicines used for treating influenza (such as
oseltamivir, which sells for 283 RBM/box in China) is
expensive for ‘developing’ countries. Hence, we need to
explore new, safe and inexpensive anti-influenza medi-
cine. BLG, which sells for 12.00 RBM/box in China,
would be a good choice.
Furthermore, according to basic science studies, the
active ingredient of IIR also exerts immune-modulating
and anti-inflammation effects in vitro and in vivo.
Polysaccharides from IIR can promote production of
interleukin-2 and interferon-γ, as well as the prolifera-
tion of lymphocytes and macrophages in mice [33]. Also,
indirubin and its derivatives can suppress the expression
of several pro-inflammatory cytokines induced by influ-
enza infection in human macrophages and alveolar epithe-
lial cells [27]. Hence, an evidence-based clinical trial to
evaluate the effectiveness of BLG in treating inflammation
induced by influenza infection certainly has merit.
In summary, we have described the first clinical trial
for treatment using a single herb against influenza A
and B viruses in China. We will hold a large-scale clin-
ical trial to comprehensively evaluate the effectiveness
and safety of BLG against influenza infection based on
the results of this pilot study.Trial status
This clinical trial was reviewed by the Ethics Committee
of the First Affiliated Hospital of Guangzhou Medical
University at the end of 2011. The first patient was
enrolled in 2012. From early 2012 to 2014 in June, 50
patients had finished the treatment and observation
cycle. This clinical trial is expected to be completed at
the end of 2015.Additional files
Additional file 1: The product inspection report of Ban-Lan-Gen
(the Chinese edition). The Ban-Lan-Gen (BLG) granules were produced
by Hutchisom Whampoa Guangzhou Baiyunshan Chinese Medicine Company
Limited. The items, including shape and properties, solubility, bacterial count,
etcetera of the BLG granules, were tested, and they conformed to the quality
requirements of the People’s Republic of China Pharmacopoeia of 2010.
Li et al. Trials  (2015) 16:126 Page 9 of 10Additional file 2: The product inspection report of placebo (the
Chinese edition). The placebo was produced by Hutchisom Whampoa
Guangzhou Baiyunshan Chinese Medicine Company Limited. The items,
including shape and properties, solubility, bacterial count, etcetera of the
placebo, were tested, and they conformed to the quality requirements of
the People’s Republic of China Pharmacopoeia of 2010.
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